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ABSTRACT 
 
Schizophrenia is a serious disorder that affects 1% of the population in the United States 
and Europe, and is associated with a significant reduction in life expectancy that 
approaches 20% compared with that of the general population. Current management of 
patients with schizophrenia involves the increasing use of atypical antipsychotic agents, 
such as risperidone, quetiapine, olanzapine, and clozapine. The use of these agents has 
been associated with increased morbidity from obesity, hyperlipidemia, development of 
new-onset diabetes, and, in rare instances, development of diabetic ketoacidosis. The 
precise mechanism for the abnormalities in carbohydrate and lipid metabolism is 
incompletely understood.. We investigated whether haloperidol and clozapine, 
respectively a typical and an atypical antipsychotics, directly affect insulin action in 
cultured cell models and in vivo. In our experimental paradigms, both haloperidol and 
clozapine reduced insulin-stimulated glucose uptake in a time- and concentration 
dependent manner, although with a different efficacy. Indeed, pre-treatment with 
clozapine, but not with haloperidol, prevented insulin effect on insulin receptor (IR) and 
IR substrate-1/2 (IRS-1/2) tyrosine phosphorylation. 
Moreover, both drugs reduced insulin-dependent phosphorylation of protein kinase C-ζ 
(PKC- ζ), and induced an insulin-independent increase of phosphorylated Akt. These 
effects were paralleled by increased expression of Ped/Pea-15, an Akt substrate and 
inducer of insulin resistance. Similar changes of these signalling proteins were detected 
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in caudate-putamen and in skeletal muscle of mice treated with either haloperidol or 
clozapine. Thus, antipsychotics may impair insulin action, at least in part, by up-
regulating Ped/Pea-15 and inhibiting activation of PKC- ζ. 
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INTRODUCTION 
Schizophrenia, Type 2 Diabetes Mellitus and Antipsychotics  
Schizophrenia is a major highly debilitating psychiatric disorder with a worldwide 
prevalence of about 1% (1). Among schizophrenic patients life expectancy is 20% 
shorter than in general population (2). This is accounted for, at least in part, by 
circulatory, respiratory and metabolic illnesses (3; 4; 5; 6). Several lines of evidence, 
replicated over many decades, have indicated that schizophrenic patients have an higher 
prevalence of impaired glucose tolerance, insulin resistance  and type 2 diabetes 
mellitus than general population (7; 8; 9). A family history of type 2 diabetes mellitus is 
found in 18-19% of schizophrenic patients as compared to 1,2-6,3 % in the general 
population (10; 11). Although the patho-physiological bases of this relationship are not 
clearly understood, a combination of genetic and environmental factors, including 
lifestyle and medications, is likely to be involved in the dysregulation of glucose 
metabolism observed in these patients (12; 13; 14). Indeed, the treatment with 
antipsychotics has been associated with weight gain, impaired glucose tolerance, insulin 
resistance and type 2 diabetes mellitus (15; 16). 
On the other hand, several reports although not all, suggestthat schizophrenia is 
associated with abnormal glucose metabolism independently of antipsychotic use. A 
few studies have investigated that diabetes has an increased prevalence in the families 
of schizophrenia probands. Mukherjee et al. (1989) described an increased prevalence 
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of type 2 diabetes mellitus (T2DM) among first-degree relatives of schizophrenia 
patients.  
One study (Spelman et al., 2007) found an increased prevalence of impaired glucose 
tolerance in an oral glucose tolerance test (GTT) in newly diagnosed, antipsychotic-
naïve patients with schizophrenia (10.8%) and their first-degree relatives (18%) 
compared to healthy controls (0%). However, the relatives and healthy controls were 
not well matched for age, body mass index (BMI), and smoking habit, which are known 
risk factors for developing diabetes.  
In summary, there are more considerable evidences that the prevalence of diabetes is 
increased in patients with schizophrenia and is linked to the use of antipsychotic 
medications. The underlying mechanism for the increased prevalence of type 2 diabetes 
in treated schizophrenic population is unknown. Several studies have failed to find a 
correlation between the duration of therapy and antipsychotic medications, and others 
have found significant differences between the older-generation antipsychotic 
medications and the newer atypical agents.  
The studies are often confounded by concomitant weight gain and dyslipidemia, which 
are known diabetic risk factors. Increased abdominal obesity, especially visceral 
obesity, can increase insulin resistance and contribute to hyperglycemia and diabetes 
both in healthy subjects and patients with schizophrenia. As diabetes occurrence is not 
always associated with weight gain, monitoring weight alone may be insufficient to 
screen for DM risk. The methods that can be used to assess the effects of medications 
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on glucose and insulin metabolism include (ranked least to most sensitive/reliable): 
random glucose, glycated haemoglobin (HbA1C), fasting plasma glucose, homeostasis 
model assessment insulin resistance (HOMA-IR), post-prandial glucose, the oral 
glucose tolerance test (OGTT) and the intravenous glucose tolerance test (IVGTT), and 
the hyperinsulinaemic-euglycaemic clamp.  
Even if an increased incidence of diabetes has been reported in schizophrenic patients 
before the introduction of the neuroleptics, and an association between glucose 
metabolism impairment and the use of first generation antipsychotic drugs (i.e. 
haloperidol) has been suggested (17), current evidence indicates that second generation 
antipsychotics, (or atypical antipsychotics) may induce hyperglycemia, exacerbation of 
existing diabetes or onset of diabetes mellitus (18; 19; 20; 21). 
Clinical data indicate a significant variability in drug-induced abnormalities on glucose 
metabolism. Clozapine and olanzapine are associated with the greatest risk of 
developing type 2 diabetes mellitus.  
Different mechanisms may be responsible for the metabolic side effects of anti-
psychotics leading to weight gain and insulin resistance and ultimately to type 2 
diabetes. 
Carbohydrate and lipid homeostasis linked to energy conservation and expenditure is 
dependent on a complex interplay of factors that regulate food intake and metabolism. 
Glucose intolerance, as seen in patients receiving atypical antipsychotic medications, 
might be expected to be influenced by defects in insulin secretion and sensitivity, 
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abnormalities in the secretion of gut hormones that promote insulin secretion, secretion 
and release of insulin counter-regulatory hormones such as glucagon, or alterations in 
the regulation of food intake via central and peripheral mechanisms. 
However, the molecular events underlying their actions are poorly understood. All 
antipsychotics share a common mechanism of dopamine D2 receptor occupancy, even 
with a different degree (22; 23). The D2 receptor family inhibits adenylyl cyclase in 
downstreaming transductional pathway. In addition to signaling through the second 
messenger 3'-5'- cyclic adenosine monophosphate (cAMP), activation of D2 receptor 
family stimulates the assembly of a complex containing β-arrestin2, protein phosphatase 
2 A (PP2A) and Akt (24). Akt, also known as protein kinase B (PKB), is a serine-
threonine kinase that has been largely studied for its role in growth factor-mediated cell 
survival, cell-cycle progression, and transcriptional regulation (25). Akt plays a pivotal 
role in the regulation of glucose metabolism. It is rapidly activated by insulin and, in 
skeletal muscle cells and adipocytes, it mediates the translocation of glucose transporter 
4 (GLUT4) onto the plasma membrane (26; 27; 28). Moreover, Akt also participates in the 
complex mechanism involved in insulin desensitization (29; 30; 31) and protection from 
apoptosis (32). The molecular mechanisms elicited by Akt are only partially known (33; 
34). Akt phosphorylates a wide variety of substrates, including the antiapoptotic protein 
Ped/Pea-15 (35). 
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Ped/Pea-15: a new potential target involved in antipsychotic-related 
diabetes 
Phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes (Ped/Pea-
15) is a cytosolic phosphoprotein widely expressed in different tissues and highly 
conserved in mammals. It binds to and modulates the function of a number of signaling 
proteins and effectors. Ped/Pea-15 binds several pro- and anti-apoptotic proteins thereby 
exerting a broad anti-apoptotic function. It also controls mitogenic signaling by binding 
extracellular-regulated kinases (ERKs) and anchoring ERKs to the cytoplasm. Indeed, 
changes in Ped/Pea-15 expression play an important role in tumor development and 
sensitivity to anti-neoplastic agents. Ped/Pea-15 binds to phospholipase D, enhancing its 
stability and increasing intracellular diacylglycerol levels. This effect, in turn, activates 
classical protein kinase C isoforms and generates resistance to insulin action on glucose 
metabolism in peripheral tissues. Protein kinase C dysregulation by Ped/Pea-15 also 
impairs glucose-stimulated insulin secretion in β cells in mice. 
Ped/Pea-15 gene maps on human chromosome 1q21–22 and is overexpressed in type 2 
diabetics as well as in the euglycemic offspring from these individuals. Interestingly, in 
these same subjects, Ped/Pea-15 levels correlate with insulin resistance. Ped/Pea-15 
cellular levels are regulated by ubiquitinylation and proteasomal degradation. However, 
run-on experiments in cultured cells from type 2 diabetic subjects demonstrated that, at 
least in part, the overexpression observed in these subjects is caused by transcriptional 
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abnormalities. The molecular details responsible for these abnormalities and the 
mechanisms responsible for Ped/Pea-15 gene regulation are still unclear. 
Ped/Pea-15 is modulated by phosphorylation at Ser116, by calcium-calmodulin kinase 
(CaMKII) and Akt (35) and at Ser104 by PKC (36; 37) (Fig. 1). Ped/Pea-15 
phosphorylation regulates its interaction with intracellular partners (38) and controls its 
proteasomal degradation (39). Increased expression of Ped/Pea-15 has been detected in 
patients with type 2 diabetes and their first degree relatives (37; 40). Moreover, transgenic 
mice overexpressing Ped/Pea-15 display abnormal glucose tolerance, insulin resistance 
and increased susceptibility to develop diabetes following weight gain (41). 
Overexpression of Ped/Pea-15 in cultured skeletal muscle cells inhibits insulin-induced 
activation of Protein kinase C- ζ (PKC- ζ), thereby impairing GLUT4 translocation and 
glucose uptake (41; 42). 
We have previously characterized the brain expression of the Ped/Pea-15 mRNA by in 
situ hybridization (Fig. 2). This brain areas involved in the expression are the 
Hippocampus (Fig. 2A), mamillary bodies (Fig. 2A), Frontal cortex (Fig. 2B) and 
entorhinal cortex (Fig. 2B) (data not published).   
Here we show, by in vivo and in vitro paradigms, that both haloperidol and clozapine 
increase Akt activity and Ped/Pea-15 protein expression in neurons and skeletal muscle 
cells. This is paralleled by decreased PKC- ζ activation and deranged insulin-stimulated 
glucose uptake. 
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MATERIALS AND METHODS 
General. Media, sera and antibiotics for cell cultures were from Invitrogen Ltd. 
(Paisley, United Kingdom). Phospho-phospho-Ser473 Akt antibodies were purchased 
from Cell Signaling Technology (Beverly MA). Actin antibody was from Sigma (St. 
Louis, MO). Antibodies directed against phospho-PKC ζ /PKC ζ, Akt, were from Santa 
Cruz Biotechnology (Santa Cruz, Calif.). IRS1, IRS2 and Phospho-Tyr antibodies were 
from Upstate Cell Signaling Technology (Lake Placid, NY). Antibodies to Ped/pea-15 
have been previously described (37). Electrophoresis and Western blot reagents were 
from Bio-Rad (Richmond, Va.). 2-deoxy-[14C] glucose and ECL reagents were from GE 
Healthcare . Other reagents were from Sigma. 
In vitro studies: 
Cell culture procedures. PC12 transplantable rat pheochromocytoma cells and L6 
cells were plated and grown in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 10% fetal bovine serum (FBS), 5% horse serum (for PC12 cells), 100 µg/ml 
streptomycin, and 100 IU/ml penicillin at 37 C in a humidified atmosphere of 95% air 
and 5% CO2.  
Drug preparation. Clozapine was a generous gift of Novartis Pharma (AG, 
Switzereland). Haloperidol was purchased by Sigma-Aldrich (Stheinheim, Germany). 
Both compounds were dissolved in Dimethyl sulfoxide (DMSO from Sigma Aldrich) at 
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the concentration needed, according to previously described procedures in similar 
experimental paradigms (43; 44; 45; 46). 
2-deoxy-glucose (2-DG) uptake. 2-deoxyglucose (2-DG) uptake was measured as 
previously reported (47). Briefly, confluent cells were incubated in DMEM 
supplemented with 0,25 % albumin for 18 h at 37 C. The medium was aspirated and 
cells were further incubated for 30 min in glucose-free buffer (5 mM KCl, 120 mM 
NaCl, 1,2 mM MgSO4, 10 mM NaHCO3, 1,3 CaCl2, 1,2 mM KH2PO4, and 20 mM 
Hepes, pH 7.8, 2% bovin serum albumin). The cells were incubated in the same buffer 
supplemented with 100 nM insulin for 30 min, and incubated for further 10 min in 
glucose-free buffer containing 2-DG (final concentration 0,2 mM) and 0,5 µCi/assay 
[14C]2-DG. The cells were finally lysed and 2-DG uptake was determined by liquid 
scintillation counting. 
Western blot analysis and immunoprecipitation. Cell lysates were 
solubilized in lysis buffer containing 50 mM HEPES pH 7.5, 150 mM NaCl, 10 mM 
EDTA, 10 mM Na4P2O7, 2 mM sodium orthovanadate, 100 mM NaF, 1 mM 
phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, 10 µg/ml leupeptin, pH 7.4, and 1% 
Triton for 2 h at 4 C. Lysates were clarified by centrifugation at 12,000 x g for 15 min at 
4 C, and aliquots were either immunoprecipitated with the indicated antibodies or 
directly separated by SDS-PAGE before analysis by Western blot, as previously 
described (48; 49). 
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In vivo studies: 
Animal care. 3-months-old male C57/BL/KsJ mice were purchwwased from the 
Charles River Laboratories (Milan, Italy). Animal were housed under 12-h light/12-h 
dark cycle in a temperature and humidity controlled colony room and were given 
pelleted food and water ad libitum in a specific pathogen-free environment. All 
procedures were conducted in accordance with the NIH Guide for Care and Use of 
Laboratory Animals (NIH Publication N0.85-23, revised, 1985) and were approved by 
local Animal Care and Use Committee. Care was taken to minimize animal number and 
sufferance. Two hours after the last injection the mice were decapitated to obtain protein 
extracts from frontal cortex (FC) and from caudate-putamen (CP) using the rat brain 
atlas by Paxinos and Watson (50) as an anatomical reference (approximately from 
Bregma 6,70 mm to 4,20 mm and from Bregma 2,20 mm to -0,40 mm for FC and CP 
respectively). 
Drug preparation and treatment. Clozapine and Haloperidol were dissolved in 
lactic acid (0.1%  in NaCl), adjusted to pH 5.5 adding NaOH and administered 
intraperitoneally to the animals. The dose of haloperidol used in these studies was 0.8 
mg/Kg for 21 days; clozapine was used at 10 mg/Kg for 21 days. The doses of both 
drugs were chosen according to previous studies showing a behavioural and 
transcriptional effect (51; 52; 53; 54; 55). The animals were sacrificed 90 min after the last 
injection. 
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Tissue collection and Immunoblotting. Tissue samples (frontal cortex, caudate 
putamen and quadriceps muscles) were rapidly collected, snap frozen in liquid nitrogen 
and stored at   -80 C for subsequent Western blotting. Tissue samples were 
homogenized in a Polytron omogenizer (Brinkman Instruments, Westbury, NY) in T-
PER TISSUE Protein Extraction Reagent buffer (25 mM bicine, 150 Mm sodium 
chloride pH 7.6, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, 10 µg/ml 
leupeptin, pH 7.4) (PIERCE Rockford, IL) according to the manufacturer's instruction. 
Total homogenates were centrifuged at 12,000 x g for 30 min at 4 C and were subjected 
to sodium dodecyl sulphate-polyacrilamide gel electrophoresis (SDS-PAGE) with 10% 
gels. Proteins separated on the gels were electroblotted onto nitrocellulose filters as 
described above and membranes were probed with specific antibodies, as indicated. 
Data Analysis A one factor analysis of variance (ANOVA) was used to analyze 
treatment effect. Any significant ANOVA were further analyzed by Student-Neuman-
Keuls post hoc test to determine the specificity of the effect. p values < 0.05 were 
considered statistically significant. 
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RESULTS 
 
Effect of haloperidol and clozapine on glucose uptake in cultured cells. 
We have evaluated 2-deoxyglucose (2-DG) uptake in PC12 cells following the 
treatment with either 12.5 µM haloperidol or 1.5 µM clozapine for 24 h. No significant 
change of basal 2-DG uptake was induced by both compounds (Fig. 3A). However, 
both haloperidol and clozapine almost completely blunted insulin effect. Comparable 
results were obtained following identical treatment of L6 myotubes (Fig. 3B). Indeed, 
insulin elicited 2-DG uptake by 25% and 45% respectively, in PC12 and in L6 cells, 
while it failed to induce significant changes in the presence of either haloperidol or 
clozapine (Fig. 3A and 3B). 
Effect of haloperidol and clozapine on insulin signalling in cultured 
cells. 
In order to investigate at what level insulin action was impaired, L6 cells have been 
incubated with 12.5 µM haloperidol or 1.5 µM clozapine for 24 h and with insulin for 
additional 30 min. No changes of the cellular content of the insulin receptor (IR) and of 
the insulin receptor substrates, (IRS1 and IRS2) were decetcted by Western Blot with 
specific antibodies (Fig. 4A). Insulin exposure increased tyrosine phosphorylation of IR, 
IRS1 and IRS2 in control and in haloperidol treated cells (Fig. 4A). At variance, 
clozapine-treated cells displayed a drastic reduction of insulin-stimulated IR, IRS1 and 
IRS2 tyrosine phosphorylation (Fig. 4A). 
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We also investigated whether PKC- ζ and Akt, two major kinases involved in the 
regulation of glucose uptake, were affected by the antipsychotic compounds. Protein 
levels of PKC- ζ were similar in untreated cells and in cells exposed to either 
haloperidol or clozapine (Fig. 4B), while insulin-induced PKC- ζ phosphorylation at 
Thr 410 was reduced by both drugs. No change in basal PKC- ζ phosphorylation was 
detected, instead. Conversely Akt cellular content was slightly increased (difference was 
not statistically significant) by both haloperidol and clozapine. 
Nevertheless, insulin-independent phosphorylation at Ser 473 (which represents an 
activation marker) was significantly increased by both compounds (p<0.05). In parallel 
with the early signalling steps, insulin effect on Akt phosphorylation was conserved 
upon haloperidol and reduced upon clozapine pre-treatment of the cells. Very consistent 
results were obtained in PC12 cells (data not shown). 
Effect of haloperidol and clozapine on Ped/Pea-15 expression. 
Next, we addressed whether haloperidol and clozapine may affect the cellular content of 
Ped/Pea- 15. Indeed, Ped/Pea-15 is an Akt substrate (35), whose overexpression causes 
insulin resistance in cellular and animal models (37; 41) and associates to insulin 
resistance in humans (40). Both haloperidol and clozapine treatment of PC12 (data not 
shown) and L6 cells (Fig. 4 B) for 24 h increased Ped/Pea-15 cellular levels. Despite a 
reduction in the absolute amount, raised Ped/Pea-15 content was also observed in the 
presence of cycloheximide (30 µM), a protein synthesis inhibitor, suggesting that, at 
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least in part, regulation occurred at post-translational level both in PC12 (Fig. 5A) and 
in L6 cells (Fig. 5B). 
Therefore, PC12 and L6 cells were incubated with raising concentrations of haloperidol 
(1-100 µM) (43; 44) and clozapine (0.1-25 µM) (43; 45) for different time points (6, 12, 24 
and 48 h), prior to measure the levels of phosphorylated Akt and Ped/Pea-15. The time- 
and concentration-dependent increase of Akt activation (Fig. 6A and 6C) closely 
paralleled that of Ped/Pea-15 cellular content, in PC12 cells (Fig. 6B and 6D), upon 
treatment with either haloperidol (Fig. 6A and 6B) and clozapine (Fig. 6C and 6D) 
(p<0.001). 
Haloperidol treatment of L6 cells (Fig.6A) was less effective, as compared to PC12 
cells, eliciting a significant Akt (p<0.001) activation as early as upon 12 h incubation 
with a concentration of 12.5 µM (Fig. 7A). Nonetheless, the regulatory effect on 
Ped/Pea-15 was consistently evident (Fig. 7B). Higher doses of haloperidol were tested 
but grossly impaired cell viability. Also, clozapine exposure led to parallel increases of 
cellular content of phosphorylated Akt (Fig. 7C) and of Ped/Pea-15 (Fig. 7D). 
In vivo effects of haloperidol and clozapine on Akt, Ped/Pea-15, and 
PKC ζ 
In order to verify whether antipsycothics may induce comparable changes in vivo, three 
groups of 8 C57/BL/KsJ mice were treated with haloperidol (0.8 mg/kg), clozapine (10 
mg/kg) or vehicle. 
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Protein extracts from caudate-putamen (CP) and frontal cortex (FC) were obtained and 
assayed by Western blot with specific antibodies. Increased levels of phosphorylated 
Akt were detected in CP (Fig. 8A), but not in FC (Fig. 8B), in the animals treated either 
with haloperidol or with clozapine. This was paralleled by increased Ped/Pea-15 
detection and reduced PKC- ζ phosphorylation in CP (Fig. 8A). A more marked 
decrease of phosphorylated PKC- ζ was observed upon clozapine treatment however 
(p<0.05). Again, no difference was detected in FC of the treated animals. 
Similarly, quadriceps muscle specimens from haloperidol- and clozapine-treated mice 
featured increased phosphorylated Akt (Fig. 9A) and Ped/Pea-15 levels (Fig. 9B) as 
well as decreased PKC- ζ phosphorylation (Fig. 9C), compared to vehicle-treated 
controls. 
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DISCUSSION 
The aim of the present study was to investigate the molecular mechanism by which 
haloperidol and clozapine may impair insulin sensitivity. Previous findings indicate that 
first and second generation antipsychotics directly worsen insulin-stimulated glucose 
transport (43; 56), thereby contributing to the abnormalities in glucose metabolism 
frequently observed in treated patients (15; 19). Indeed, glucose transport in insulin-
sensitive tissues is rate-limiting for glucose metabolism, and impairments in this system 
may represent key abnormalities in inducing insulin resistance. 
Our data show that exposure of PC12 and L6 cells, representative of neuron and skeletal 
muscle cells, respectively, to both haloperidol and clozapine caused an inhibition of 
insulin-stimulated glucose uptake. We have therefore evaluated whether different 
effectors of the insulin signal transduction cascade may be responsible for this 
impairment. 
We showed that insulin receptor tyrosine auto-phosphorylation and kinase activity and 
insulin-stimulated Akt phosphorylation were differentially affected by typical and 
atypical antipsychotics being impaired in cells pre-treated with clozapine, while 
remaining unchanged after treatment with haloperidol. Thus, clozapine, but not 
haloperidol, impairs the early events of insulin signalling. On the other hand, common 
pathways were also affected by both antipsychotic drugs. Indeed, in the absence of 
insulin, phosphorylated Akt was increased following treatment with either haloperidol 
and clozapine. Moreover, insulin stimulation of PKC- ζ phosphorylation was drastically 
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impaired by both compounds, while protein content did not change. The increased Akt 
phosphorylation is consistent with previous observations suggesting that this protein 
represents a potential target of antipsychotic drugs (44). For example, it has been 
reported that clozapine activates Akt via phosphoinositide-3 kinase (PI3-K) signaling 
cascade (45; 46; 57). Other studies showed an increase of Akt phosphorylation by 
haloperidol (58; 59; 60). In addition, Akt has been envisioned as one of the potential 
schizophrenia susceptibility genes (61; 62).Alterations in Akt-GSK 3 α/β signalling likely 
contribute to the pathogenesis of schizophrenia (60; 63). Thus, one might speculate, that 
both haloperidol and clozapine may operate by enhancing Akt function, thereby 
counteracting the defect in schizophrenic patients (58). 
However whether the increase of Akt phosphorylation induced by the antipsychotic 
compounds might also be involved in the impairment of insulin action on glucose 
uptake is less intuitive. Indeed, Akt is rapidly stimulated by insulin and mediates many 
insulin signals, including glucose uptake in different cellular systems (64; 65). In addition, 
insulin-stimulated Akt phosphorylation is reduced in adipocytes of type 2 diabetic 
patients and in skeletal muscle of impaired-glucose tolerant (IGT) individuals compared 
with control subjects (66; 67; 68), although these observations are not consistent in all the 
studies (69; 70; 71). On the other hand, Akt is also involved in insulin desensitization (30; 
31), and increased Akt has been detected in several models of insulin resistance (72). 
Thus, it could be hypothesized that long term treatment with haloperidol and clozapine 
may induce persistent upregulation of Akt, which in turn may impair insulin signalling. 
 22 
One of the potential mechanisms by which Akt may affect insulin signalling is the 
increase of Ped/Pea-15 protein stability (35). Indeed, Ped/Pea-15 is phosphorylated by 
Akt at serine 116 (35). This stabilizes the protein, likely preventing its degradation in the 
proteasomes (35; 39). Increased expression of Ped/Pea-15 has been associated to type 2 
diabetes in humans (37; 40). Moreover, forced expression in mice and in cultured cells 
inhibits insulin action on glucose uptake by impairing PKC- ζ activation (41; 42). 
Defective activation of PKC-ζ has been also found in skeletal muscle biopsies taken 
during  hyperinsulinaemic/euglycaemic clamp assay of obese and type 2 diabetic 
subjects (68; 71). 
Ped/Pea-15 is also involved in the regulation of apoptotic cell death. Different 
experimental findings have suggested that overexpression of Ped/Pea-15 protects 
against stress-induced apoptosis (35; 39; 72). This antiapoptotic activity depends on 
phosphorylation of Ped/Pea-15 at Ser116. Thus, it is conceivable that elevated Ped/Pea-
15 levels due to Akt activation, may contribute to the antiapoptotic action of 
antipsychotics in specific subsets of neurons. Indeed it has been suggested that 
antipsychotics may exhert a protective effect by up-regulation of Akt activity (44; 45; 73).  
Raised Ped/Pea-15 levels may contribute to the potential neuroprotective effect, but also 
to the diabetogenic side effect of such compounds, impairing insulin action in peripheral 
tissues. Our data are consistent with the hypothesis that haloperidol and clozapine 
increase Akt activity, thereby causing hyperphosphorylation of Ped/Pea-15 at serine 116 
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(data not shown) and reducing its degradation. Intracellular accumulation of Ped/Pea-15 
impairs activation of PKC- ζ  and insulin-stimulated glucose uptake. 
These observations are supported by the increased Akt phosphorylation and Ped/Pea-15 
expression and decreased PKC- ζ phosphorylation found in the caudate-putamen of 
mice treated with either haloperidol or clozapine. This is a significant finding since the 
caudate putamen is a preferential target of D2-antagonists (52; 75). It is also intriguing 
that quadriceps muscles feature similar changes of the above signalling molecules and, 
together with data in the L6 cells, suggest that the skeletal muscle may represent a direct 
target, as well.  
Moreover, it should be pointed out that clozapine, at variance with haloperidol, 
drastically decreases the early steps of insulin action, i.e. receptor and IRS 
phosphorylation. This is consistent with the higher impact exerted by several atypical 
antipsychotics on glucose tolerance (76). The mechanisms responsible for such 
alterations have not been identified, but they may also involve the increases of Akt, 
since, as previously reported, its hyper-activation impairs IRS1 function, and may affect 
receptor activity as well (77; 78). One might speculate that a different subcellular 
localization of Akt following exposure to clozapine may direct its function toward 
specific substrates. Alternative explanation could be searched in the different 
pharmacologic profile of the two antipsychotics (i.e. different affinity for and 
occupancy of dopamine receptors by clozapine compared to haloperidol). 
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In summary, our data suggest that first and second generation antipsychotics may 
contribute, with different degree and by acting at different level on transductional 
cascade of insulin, to the impairment of glucose metabolism. The molecular mechanism 
implicated in this effect involves intracellular effectors of the insulin signaling cascade. 
For instance, the increase of Akt activity enhances the levels of Ped/Pea- 15 by 
increasing its phosphorylation on Ser 116; as a consequence, Ped/Pea-15 inhibits the 
activation of atypical PKC- ζ and prevents insulin-stimulated glucose uptake. 
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FIGURE LEGENDS 
 
Figure 1. Ped/Pea-15 protein function and structure. Ped/Pea-15 is a 
ubiquitously expressed cytosolic protein which is modulated by 
phosphorylation at Ser116, by calcium-calmodulin kinase (CaMKII) and 
Akt and at Ser104 by PKC. Ped/Pea-15 gene maps on human chromosome 
1q21–22. It binds to and modulates the function 
of a number of signaling proteins and effectors and thus exerts its two 
mainly function in protection from apoptosis  control of glucose transport.   
Figure 2.  Ped/Pea-15 location in brain by In situ Hybridization. We have 
detected the pattern of expression of Ped/Pea-15 by in situ hybridization 
using [35S]-labeled antisense riboprobes. It is expressed in Hippocampus 
(A’), mamillary bodies (A’’), Frontal cortex (B’) and entorhinal cortex 
(B’’). 
Figure 3. Antipsychotics inhibit insulin-stimulated glucose uptake in PC12 
and L6 cells. 2-deoxyglucose uptake was measured in PC12 (A) and L6 
cells (B) after treatment for 24 h with haloperidol (12.5 µM) and clozapine 
(1.5 µM as indicated). Control cells received vehicle (DMSO) instead of 
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drugs. Cells were then exposed to 100 nM insulin as described in 
MATERIAL AND METHODS. Bars represent the means + SD of 
triplicate determination in four independent experiments. The significant 
differences (vs control), were determined by one factor analysis of variance 
(ANOVA). Positive samples were further analyzed by Student-Neuman-
Keuls post hoc test to determine the specificity of the effect. p values < 
0.001 were indicated by asterisks, ***. 
Figure 4. Effect of haloperidol and clozapine on insulin signaling in 
cultured cells. 
L6 cells have been incubated with haloperidol 12.5 µM and clozapine 1.5 
µM for 24 hours and with insulin 100 nM for further 30 min. (A) Protein 
extracts were immunoprecipitated with anti IR (α- subunit), IRS-1 and IRS-
2 antibodies, subjected to Western blotting (WB) with anti-
phosphotyrosine, IR (β-subunit), IRS-1 and IRS-2 antibodies, as indicated. 
(B) Cell lysates were blotted with phospho-Ser- 473 Akt or phospho-Thr 
410 PKCζ followed by reblotting with total Akt and PKCζ respectively and 
with Ped/Pea-15 antibodies. Equal loading of the samples was ensured by 
control blot with anti-actin antibododies. The blots were revealed by ECL 
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and autoradiography. The blots shown are representative of four 
independent experiments. 
Figure 5. Haloperidol and Clozapine increase Ped/Pea-15 expression. The 
PC12 (A) and L6 (B) cells have been treated with haloperidol 12.5 µM and 
clozapine 1.5 µM for 24 h with or without cycloheximide 30µM (CHX), a 
protein synthesis inhibitor. Cells were lysed as described and lysates were 
blotted with anti Ped/Pea-15 antibody. Equal loading of the samples was 
ensured by control blot with anti-actin antibododies. The blots were 
revealed by ECL and autoradiography and subjected to densitometric 
analysis as described in Material and Methods. The blots shown are 
representative of four independent experiments. The significant differences 
(vs control), were determined by ANOVA. Student-Neuman-Keuls post 
hoc test was used to determine specificity of the effect. p values < 0.001 
were indicated by asterisks, ***. 
Figure 6. Effect of antipsychotics on Ped/Pea-15 and Akt in PC12 cells. 
PC12 cells were incubated for different times with increasing 
concentrations of haloperidol(A-B) and clozapine (C-D) as indicated. The 
cells were lysed as described, lysates were subjected to Western blotting 
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with phospho-Ser-473 Akt and Ped/Pea-15 antibodies and then reblotted 
with total Akt antibody. Equal loading of the samples was ensured by 
control blot with anti-actin antibododies. The blots were revealed by ECL 
and autoradiography. For phophorylated Akt, values were expressed as 
percent of P-Akt/Akt levels, for Ped/Pea-15 as arbitrary units derived from 
densitometric analysis, 
further normalized on actin values, and shown with the bars. Data represent 
the means + S.D. from at least three experiments. ANOVA and Student-
Neumans-Keuls post hoc test analysis revealed significant differences from 
the controls, *** p<0.001. 
Figure 7. Effect of antipsychotic drugs at on Ped/Pea-15 and Akt in L6 
cells. The L6 cells were incubated for different times with increasing 
concentrations of haloperidol (A-B) and clozapine(C-D) as indicated. The 
cells were lysed as described, subjected to Western blotting with phospho-
Ser-473 Akt (pAkt) and Ped/Pea-15 and reblotting for total Akt. Equal 
loading of the samples was ensured by control blot with anti-actin 
antibododies. The blots were revealed by ECL and autoradiography. For 
phophorylated Akt, values were expressed as percent of P-Akt/Akt levels, 
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for Ped/Pea-15 as arbitrary units derived from densitometric analysis, 
further normalized on actin values, and shown with the bars. Data represent 
the means + S.D. from at least three experiments. ANOVA and Student-
Neumans-Keuls post hoc test analysis revealed significant differences from 
the controls, *** P<0.001. 
Figure 8. Haloperidol and clozapine effect in frontal cortex and caudate 
putamen. 
Three groups of 8 mice were treated once a day for 21 days with single 
injection of saline, haloperidol (0.8 mg/kg) and clozapine (10 mg/kg). 
Phospho-Ser-473 Akt (pAkt), phospho-PKCζ and Ped/Pea-15 levels were 
measured in caudate putamen (A) frontal cortex (B), 30’ after the last 
injection of drugs or saline. Equal loading of the samples was ensured by 
control blot with antiactin antibododies. Phosphorilated Akt and PKC ζ 
were expressed as percent of P-Akt/Akt and P-PKCζ/PKCζ levels, 
Ped/Pea-15 as arbitrary units derived from densitometric analysis. Values 
were further normalized on actin values. Significant differences have been 
indicated by asterisks, *p<0.05, ***p<0.001. 
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Figure 9. Haloperidol and clozapine effect in quadriceps muscle. Mice 
were treated as described in fig.6 and sacrificed. Quadriceps were isolated 
and homogenated. Homogenates were then analyzed by WB as described in 
Fig.6. Equal loading of the samples was ensured by control blot with anti-
actin antibododies. Phosphorilated Akt and PKCζ were expressed as 
percent of P-Akt/Akt and p-PKCζ/PKCζ levels, Ped/Pea-15 as arbitrary 
units derived from densitometric analysis. Values were further normalized 
on actin values. Significant differences have been indicated by asterisks, 
*p<0.05,**p< 0.01, ***p<0.001 
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